Pharmacological Profile of the “Triple” Monoamine Neurotransmitter Uptake Inhibitor, DOV 102,677

@article{Popik2006PharmacologicalPO,
  title={Pharmacological Profile of the “Triple” Monoamine Neurotransmitter Uptake Inhibitor, DOV 102,677},
  author={Piotr Popik and Martyna Krawczyk and Krystyna Gołembiowska and Gabriel Nowak and Aaron Janowsky and Phil Skolnick and Arnold Stan Lippa and Anthony S Basile},
  journal={Cellular and Molecular Neurobiology},
  year={2006},
  volume={26},
  pages={855-871}
}
Summary1. The molecular and behavioral pharmacology of DOV 102,677 is characterized.2. This characterization was performed using radioligand binding and neurotransmitter uptake assays targeting the monoamine neurotransmitter receptors. In addition, the effects of DOV 102,677 on extracellular neurotransmitter levels were investigated using in vivo microdialysis. Finally, the effects of DOV 102,677 in the forced swim test, locomotor function, and response to prepulse inhibition was investigated.3… 
Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor.
TLDR
Preliminary evidence of a clinically meaningful antidepressant action with a molecule capable of inhibiting the three transmitters most closely linked to major depressive disorder is provided.
Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity
TLDR
The enhancement of serotonin, NE, and DA in rat brain regions associated with depression suggest that amitifadine may have novel antidepressant activity.
D-161, a novel pyran-based triple monoamine transporter blocker: behavioral pharmacological evidence for antidepressant-like action.
TLDR
Results suggest that the novel asymmetric pyran derivative D-161 with unique molecular structure exhibiting triple monoamine transporter inhibitory activity could possess potent antidepressant activity.
Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB‐1020: Implications for treatment of attention‐deficit hyperactivity disorder
TLDR
EB‐1020 dose‐dependently inhibited locomotor hyperactivity in juvenile rats lesioned with the neurotoxin 6‐hydroxydopamine as neonates; a well‐established animal model for attention‐deficit hyperactivity disorder (ADHD).
The Design, Synthesis and Structure–Activity Relationship of Mixed Serotonin, Norepinephrine and Dopamine Uptake Inhibitors
TLDR
Preclinical studies and clinical trials indicate that a drug inhibiting the reuptake of all three of these neurotransmitters could produce more rapid onset of action and greater efficacy than traditional antidepressants.
Effect of DOV 102,677 on the volitional consumption of ethanol by Myers' high ethanol-preferring rat.
TLDR
DOV 102,677 significantly decreased the volitional consumption of ethanol with minimal alterations in the intake of food or on body weight in an ethanol-preferring rat strain, suggesting that triple reuptake inhibitors may find utility in treating alcohol abuse.
Effects of the triple monoamine uptake inhibitor DOV 102,677 on alcohol-motivated responding and antidepressant activity in alcohol-preferring (P) rats.
TLDR
It is proposed that DOV may be useful in treating comorbid alcoholism and depression in humans and the elimination kinetics of DOV suggests that its long duration of action may be due to an active metabolite.
Antidepressant-Like Pharmacological Profile of a Novel Triple Reuptake Inhibitor, (1S,2S)-3-(Methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS)
Due to the putative involvement of dopaminergic circuits in depression, triple reuptake inhibitors are being developed as a new class of antidepressant, which is hypothesized to produce a more rapid
The putative antidepressant DOV 216,303, a triple reuptake inhibitor, increases monoamine release in the prefrontal cortex of olfactory bulbectomized rats.
TLDR
Treatment with DOV 216,303 leads to increased extracellular levels of serotonin and norepinephrine neurotransmission, but also increased dopamine levels in OBX animals as well as their controls, but a challenge in chronically treated animals resulted in lower monoamine concentrations than the same challenge in untreated animals.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 47 REFERENCES
Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor.
Strategies to Optimize the Antidepressant Action of Selective Serotonin Reuptake Inhibitors
TLDR
Unlike TCAs, the SSRIs display little affinity for aminergic receptors and therefore lack the severe side effects associated with the use of the former agents, which results in both an improved quality of life for the patients and greater treatment compliance, which is compromised in some instances by theUse of TCAs.
"Broad spectrum" antidepressants: is more better for the treatment of depression?
TLDR
Based on the pivotal role proposed for dopamine in depression, it has been hypothesized that a broad spectrum antidepressant will produce a more rapid onset and/or higher efficacy than agents inhibiting the reuptake of serotonin and or norepinephrine.
Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization.
TLDR
A Na(+)- and Cl(-)-coupled serotonin (5-hydroxytryptamine, 5HT) transporter is expressed on human neuronal, platelet, placental, and pulmonary membranes and sequence analysis reveals a 630-amino acid open reading frame bearing 92% identity to the cloned rat brain 5HT transporter.
The Structure and Function of Norepinephrine, Dopamine, and Serotonin Transporters
Our first insights into the transport of monoamines came nearly 40 yrs ago when Axelrod et al. (7) injected [3H]-epinephrine (EPI) into the femoral vein of anesthetized male rats in order to
Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat: A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder
TLDR
It is hypothesized that the atomoxetine-induced increase of catecholamines in PFC, a region involved in attention and memory, mediates the therapeutic effects of atomxetine in ADHD.
Drug interactions with the dopamine transporter in cryopreserved human caudate.
TLDR
The data suggest that cryopreserved human caudate can be used to characterize drug interactions with the DAT, and that HEK-hDAT cells provide a comparable system for modeling the initial interaction of drugs with native hDAT.
A role for presynaptic mechanisms in the actions of nomifensine and haloperidol
TLDR
The results suggest that a dopaminergic presynaptic site is a target of systemically applied psychomotor stimulants and regulates the postsynaptic action of neuroleptics during behavior, and indicates thatPresynaptic mechanisms may play a more important role in DA-behavior relationships than is currently thought.
DOV 216,303, a “Triple” Reuptake Inhibitor: Safety, Tolerability, and Pharmacokinetic Profile
TLDR
Plasma concentrations of DOV 216,303 after doses >10 mg exceed its reported IC50 values for inhibition of biogenic amine reuptake, and is safe and well tolerated both at single doses of up to 100 mg and multiple doses of 100 mg/day for 10 days.
Release of dopamine via the human transporter.
TLDR
The ability to define classes of uptake blockers based on their effects on human transporter-mediated dopamine efflux may lead to the identification of structural features of the transporter that differentiate abused from nonabused drugs.
...
1
2
3
4
5
...